FDA Approves Medtronic's Leadless Pacemaker With Large Postmarket Trial Condition
This article was originally published in The Gray Sheet
Executive Summary
As a condition of approval for the Micra pacer, Medtronic has agreed to conduct a post-approval study with at least 1,830 “real-world” patients, according to the company.
You may also be interested in...
St. Jude Pauses LEADLESS II Trial Of Nanostim Following Reports Of Lost Telemetry
No patient injuries related to the Nanostim issues have been reported, but it puts St. Jude further behind Medtronic and Boston Scientific in the emerging leadless pacemaker market. The company says the problem reported with seven Nanostim devices is not related to the lithium-deposit problem that recently caused batter depletion in some of its high voltage devices.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.